Literature DB >> 29849120

The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer.

Jung-Jin Park1, Mee-Hee Park1,2, Eun Hye Oh1, Nak-Kyun Soung3, Soo Jae Lee4, Jae-Kyung Jung4, Ok-Jun Lee5, Seok Joong Yun6, Wun-Jae Kim6, Eun-Young Shin7, Eung-Gook Kim8.   

Abstract

Epithelial-mesenchymal transition (EMT) facilitates cancer invasion and metastasis and thus accelerates cancer progression. p21-activated kinase 4 (PAK4) is a critical regulator of prostate cancer (PC) progression. Here, we report that PAK4 activation promotes PC progression through the EMT regulator Slug. We find that phosphorylated PAK4S474 (pPAK4) levels, an index of PAK4 activation, were tightly associated with Gleason score (p < 0.001), a clinical indicator of PC progression, but not with prostate serum antigen levels or tumor stage. Stable silencing of PAK4 in PC cells reduced their potential for EMT, cellular invasion, and metastasis in vivo. PAK4 bound and directly phosphorylated Slug at two previously unknown sites, S158 and S254, which resulted in its stabilization. The non-phosphorylatable form SlugS158A/S254A upregulated transcription of CDH1, which encodes E-cadherin, and thus suppressed EMT and invasion, to a greater extent than did wild-type Slug. The strong EMT inducer TGF-β elevated pPAK4 and pSlugS158 levels; PAK4 knockdown or introduction of a dominant-negative form of PAK4 inhibited both TGF-β-stimulated EMT and an increase in pSlugS158 levels. Finally, immunohistochemistry revealed a positive correlation between pPAK4 and pSlugS158 but an inverse correlation between pSlugS158 and E-cadherin. The results suggest that the PAK4-Slug axis represents a novel pathway that promotes PC progression.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29849120     DOI: 10.1038/s41388-018-0327-8

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

1.  P21 activated kinase-1 mediates transforming growth factor β1-induced prostate cancer cell epithelial to mesenchymal transition.

Authors:  Ahmad Al-Azayzih; Fei Gao; Payaningal R Somanath
Journal:  Biochim Biophys Acta       Date:  2015-03-06

2.  Pak1 phosphorylation of snail, a master regulator of epithelial-to-mesenchyme transition, modulates snail's subcellular localization and functions.

Authors:  Zhibo Yang; Suresh Rayala; Diep Nguyen; Ratna K Vadlamudi; Shiuan Chen; Rakesh Kumar
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

3.  GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug.

Authors:  S-H Kao; W-L Wang; C-Y Chen; Y-L Chang; Y-Y Wu; Y-T Wang; S-P Wang; A I Nesvizhskii; Y-J Chen; T-M Hong; P-C Yang
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

4.  Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.

Authors:  Zhao-Qiu Wu; Xiao-Yan Li; Casey Yuexian Hu; Michael Ford; Celina G Kleer; Stephen J Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

5.  DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.

Authors:  D-W Wu; M-C Lee; J Wang; C-Y Chen; Y-W Cheng; H Lee
Journal:  Oncogene       Date:  2013-04-15       Impact factor: 9.867

Review 6.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.

Authors:  Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2016-02       Impact factor: 6.394

Review 7.  PAKs in Human Cancer Progression: From Inception to Cancer Therapeutic to Future Oncobiology.

Authors:  R Kumar; D-Q Li
Journal:  Adv Cancer Res       Date:  2016-02-23       Impact factor: 6.242

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 9.  Tackling Cancer Stem Cells via Inhibition of EMT Transcription Factors.

Authors:  Megan Mladinich; Diane Ruan; Chia-Hsin Chan
Journal:  Stem Cells Int       Date:  2016-10-20       Impact factor: 5.443

10.  TGFβ-induced invasion of prostate cancer cells is promoted by c-Jun-dependent transcriptional activation of Snail1.

Authors:  Noopur Thakur; Shyam Kumar Gudey; Anders Marcusson; Jing Yi Fu; Anders Bergh; Carl-Henrik Heldin; Marene Landström
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

View more
  19 in total

1.  The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.

Authors:  Michelle Shen; Shiqin Liu; Tanya Stoyanova
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

2.  pSlugS158 immunohistochemistry is a novel promising mitotic marker for FFPE samples: a pilot study.

Authors:  Chang Gok Woo; Seung-Myoung Son; Young Hyun Lim; Dakeun Lee; Jung-Jin Park; Eung-Gook Kim; Eun-Young Shin; Ok-Jun Lee
Journal:  Virchows Arch       Date:  2021-09-11       Impact factor: 4.064

3.  Therapeutically actionable PAK4 is amplified, overexpressed, and involved in bladder cancer progression.

Authors:  Darshan S Chandrashekar; Balabhadrapatruni V S K Chakravarthi; Alyncia D Robinson; Joshua C Anderson; Sumit Agarwal; Sai Akshaya Hodigere Balasubramanya; Marie-Lisa Eich; Akhilesh Kumar Bajpai; Sravanthi Davuluri; Maya S Guru; Arjun S Guru; Gurudatta Naik; Deborah L Della Manna; Kshitish K Acharya; Shannon Carskadon; Upender Manne; David K Crossman; James E Ferguson; William E Grizzle; Nallasivam Palanisamy; Christopher D Willey; Michael R Crowley; George J Netto; Eddy S Yang; Sooryanarayana Varambally; Guru Sonpavde
Journal:  Oncogene       Date:  2020-03-30       Impact factor: 9.867

4.  Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma.

Authors:  Ho Won Kang; Xuan Mei Piao; Hee Youn Lee; Kyeong Kim; Sung Pil Seo; Yun Sok Ha; Yeong Uk Kim; Won Tae Kim; Yong June Kim; Sang Cheol Lee; Wun Jae Kim; Eun Young Shin; Eung Gook Kim; Seok Joong Yun
Journal:  Investig Clin Urol       Date:  2021-05-17

Review 5.  PAK4 signaling in health and disease: defining the PAK4-CREB axis.

Authors:  Eun-Young Shin; Eung-Gook Kim; So-Yoon Won; Jung-Jin Park
Journal:  Exp Mol Med       Date:  2019-02-12       Impact factor: 8.718

6.  Identification of key pathways and genes in colorectal cancer to predict the prognosis based on mRNA interaction network.

Authors:  Hengzhou Zhu; Yi Ji; Wenting Li; Mianhua Wu
Journal:  Oncol Lett       Date:  2019-08-01       Impact factor: 2.967

7.  UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells.

Authors:  Yan Wu; Dan Jin; Xiaohong Wang; Jing Du; Weihua Di; Jiajia An; Cuijie Shao; Jiwei Guo
Journal:  J Oncol       Date:  2019-01-01       Impact factor: 4.375

8.  CBP-mediated Slug acetylation stabilizes Slug and promotes EMT and migration of breast cancer cells.

Authors:  Xiaoyan Dai; Yanli Xin; Weizhi Xu; Xinxia Tian; Xiaofan Wei; Hongquan Zhang
Journal:  Sci China Life Sci       Date:  2020-07-29       Impact factor: 6.038

9.  PAK4 phosphorylating RUNX1 promotes ERα-positive breast cancer-induced osteolytic bone destruction.

Authors:  Lina Tang; Yunling Gao; Yongqi Song; Yang Li; Yanshu Li; Hongyan Zhang; Danni Li; Jiabin Li; Caigang Liu; Feng Li
Journal:  Int J Biol Sci       Date:  2020-05-25       Impact factor: 6.580

10.  Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.

Authors:  Chaping Cheng; Zhongzhong Ji; Yaru Sheng; Jinming Wang; Yujiao Sun; Huifang Zhao; Xiaoxia Li; Xue Wang; Yuman He; Jufang Yao; Li Wang; Chenlu Zhang; Yanjing Guo; Jianming Zhang; Wei-Qiang Gao; Helen He Zhu
Journal:  Theranostics       Date:  2018-09-09       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.